Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.64 |
| ▸ | CTSS | P25774 | 10/20 | 0.62 |
| ▸ | CTSL | P07711 | 4/20 | 0.62 |
| ▸ | CTSV | O60911 | 1/20 | 0.62 |
| ▸ | CTSB | P07858 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169940 | 1.00 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL8107175 | 1.00 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL1169411 | 1.00 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL6123421 | 0.99 | CTSK (0.65) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL3266068 | 0.99 | CTSK (0.65) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL3543908 | 0.92 | CTSK (0.65) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL3543820 | 0.92 | CTSK (0.65) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL1480676 | 0.92 | CTSK (0.75) | CTSKCTSSCTSL | |
| SCHEMBL1482439 | 0.92 | CTSK (0.75) | CTSKCTSSCTSL | |
| SCHEMBL3544635 | 0.92 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167507-B1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2016-03-02 | — | — | EP | disclosed |
| US-8466158-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-8466158-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-08-30 | — | — | US | disclosed |
| US-8198283-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2012-06-12 | — | — | US | disclosed |
| US-8198283-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2012-06-12 | — | — | US | disclosed |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-7893067-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-7893067-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-20090023748-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023748-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | CTSK 1/4885CTSS 7/4885CTSL 2/4885 |
| US-20090023748-A1 | Cysteine Protease Inhibitors | CTSK, CTSL, CTSV | CTSK 1/4885CTSS 7/4885CTSL 2/4885 |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | CTSK 1/4885CTSS 7/4885CTSL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.